Expression and clinical significance of centrosomal protein 55 in T-cell lymphoma

Journal of Cancer Research and Therapeutics

Volumn 14, Issue 1, 2018, Pages 94-98

  Xu, Yangyang ^a   Zhou, Xiangxiang ^a   Li, Ying ^a   Zhang, Ya ^a   Wang, Xin ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Cell viability; centrosomal protein 55; Ki 67; T cell lymphoma

Indexed keywords

CENTROSOMAL PROTEIN 55; CHOLECYSTOKININ OCTAPEPTIDE; PROTEIN DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CEP55 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL ASSAY; CELL VIABILITY; CENTROSOME; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE HYPERPLASIA; MALE; PROTEIN EXPRESSION; T CELL LYMPHOMA; GENE EXPRESSION; GENETICS; METABOLISM; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

APOPTOSIS; BIOMARKERS, TUMOR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL; MALE; NUCLEAR PROTEINS; PROGNOSIS;

EID: 85043694260     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/jcrt.JCRT_758_17     Document Type: Article

References (18)

1. Vose JM. Peripheral T-cell non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2008;22:997-1005. x.
2. Bo J, Zhao Y, Zhang S, Hua W, Wang S, Gao C, et al. Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma. J Cancer Res Ther 2016;12:1189-97.
3. Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2007;31:673-82.
4. Hou Y, Zhao X, Chen J, Zhou J, Chen W, Mao H, et al. Effects of Macrothele raven venom on intrarenal invasion and metastasis of H22 liver cancer cells in mice. J Cancer Res Ther 2017;13:725-9.
5. Fabbro M, Zhou BB, Takahashi M, Sarcevic B, Lal P, Graham ME, et al. Cdk1/Erk2-And plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell 2005;9:477-88.
6. Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna KK. Beyond cytokinesis: The emerging roles of CEP55 in tumorigenesis. Oncogene 2016;35:683-90.
7. Wang Y, Jin T, Dai X, Xu J. Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells. Biosci Trends 2016;10:67-73.
8. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, et al. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One 2009;4:e5052.
9. Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol 2014;35:4389-99.
10. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189.
11. Eskandari E, Heidarian E, Amini SA, Saffari-Chaleshtori J. Evaluating the effects of ellagic acid on pSTAT3, pAKT, and pERK1/2 signaling pathways in prostate cancer PC3 cells. J Cancer Res Ther 2016;12:1266-71.
12. Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 2013;13:234-44.
13. Geng L, Lu K, Li P, Li X, Zhou X, Li Y, et al. GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3. Oncotarget 2017;8:48701-10.
14. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
15. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-20.
16. Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E, et al. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009;32:474-85.
17. Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y, et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene 2006;25:480-6.
18. Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 2010;46:536-42.